Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPIVITE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Obsessive-compulsive disorder,Social anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder,Bulimia nervosa
Hypertension
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic via CYP2D6, CYP2C9, CYP3A4, and CYP2C19; major active metabolite: norfluoxetine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
98% bound to albumin and alpha-1-acid glycoprotein
~90%, primarily to albumin
Vd 0.25 L/kg (0.18-0.33 L/kg); indicates predominantly extracellular distribution
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 75% (range 60-85%); food decreases bioavailability by 20%
Oral: 50–60% (extensive first-pass metabolism)
GFR >= 60 m L/min: no adjustment. GFR 30-59 m L/min: 1.2 mg/kg IV every 12 hours. GFR 15-29 m L/min: 0.8 mg/kg IV every 12 hours. GFR < 15 m L/min: 0.5 mg/kg IV every 12 hours.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: 1.2 mg/kg IV every 12 hours. Child-Pugh C: 0.9 mg/kg IV every 12 hours.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
2 mg/kg IV every 12 hours for children 1-12 years; maximum single dose 100 mg. For infants 1-12 months: 2.5 mg/kg every 12 hours.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at lowest adult dose; consider 1.2 mg/kg IV every 12 hours if Cr Cl >= 60 m L/min. Monitor renal function closely; reduce dose per renal adjustment if Cr Cl < 60 m L/min.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Serotonin syndrome; bleeding risk; activation of mania/hypomania; hyponatremia; QT prolongation; weight loss in children; sexual dysfunction; withdrawal reactions; drug interactions with MAOIs, other serotonergics.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Concurrent use with MAOIs or within 14 days of MAOI therapy; known hypersensitivity to fluoxetine; use with pimozide or thioridazine due to QT prolongation risk.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-protein meals with enzyme as they may reduce effectiveness. Do not take with acidic foods (e.g., citrus, vinegar) which may degrade the enzyme. Alcohol may increase GI side effects.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid in pregnancy.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Contraindicated in breastfeeding. M/P ratio not established; potential for infant toxicity due to accumulation in breast milk.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No safe dose in pregnancy. If inadvertent exposure, discontinue immediately and provide supportive care. Pharmacokinetic changes in pregnancy increase clearance by 30-40%, but contraindication overrides any dose adjustment.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
SERPIVITE (serrapeptase) is a proteolytic enzyme used for its anti-inflammatory and mucolytic effects. It is not a standard pharmaceutical; verify regulatory status. Monitor for bleeding risk when used with anticoagulants. Onset of action may be delayed; not for acute conditions. Use with caution in peptic ulcer disease.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take on an empty stomach at least 30 minutes before or 2 hours after meals.,Do not crush or chew enteric-coated tablets; swallow whole.,Report signs of bleeding (easy bruising, nosebleeds, blood in stool).,Avoid use if allergic to enzymes or if you have a bleeding disorder.,Consult healthcare provider before use if pregnant, breastfeeding, or on anticoagulants.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPIVITE vs ALDORIL 15, answered by our medical review team.
SERPIVITE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPIVITE and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPIVITE is: 1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPIVITE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPIVITE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of feta. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.